Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models
Lubet, Ronald, Steele, Vernon, Juliana, M., Bode, Ann, Moeinpour, Fariba, Grubbs, ClintonLanguage:
english
Journal:
Oncology Reports
DOI:
10.3892/or.2018.6313
Date:
March, 2018
File:
PDF, 534 KB
english, 2018